Curated News
By: NewsRamp Editorial Staff
August 11, 2025
Quantum BioPharma Advances Lucid-MS for MS Treatment in Phase 2 Trial
TLDR
- Quantum BioPharma's agreement to produce Lucid-MS could position it as a leader in MS treatment, offering a competitive edge in the biopharmaceutical market.
- Quantum BioPharma's subsidiary has partnered with a CDMO to develop an oral formulation of Lucid-MS, advancing toward Phase 2 clinical trials for MS treatment.
- Lucid-MS's potential to restore mobility in MS patients represents a significant step toward improving quality of life for those with neurodegenerative diseases.
- Discover how Quantum BioPharma's Lucid-MS, a neuroprotective compound, could revolutionize MS treatment by reversing myelin degradation in preclinical models.
Impact - Why it Matters
This news is a beacon of hope for individuals suffering from multiple sclerosis and other neurodegenerative diseases. The advancement of Lucid-MS into Phase 2 clinical trials represents a potential breakthrough in treating the underlying causes of MS, offering the possibility of restoring mobility and improving quality of life for patients. The collaboration between Quantum BioPharma and a leading manufacturing organization underscores the importance of innovative partnerships in accelerating the development of life-changing therapies. This development not only highlights the progress in neurodegenerative disease research but also emphasizes the critical role of biopharmaceutical companies in addressing unmet medical needs.
Summary
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has taken a significant step forward in its mission to combat neurodegenerative diseases by announcing a partnership with a leading contract development and manufacturing organization. This collaboration aims to produce an oral formulation of Lucid-MS, a groundbreaking neuroprotective compound, for an upcoming Phase 2 clinical trial. Lucid-MS has shown promise in preclinical studies, demonstrating the ability to prevent demyelination and potentially restore mobility in individuals with multiple sclerosis (MS). This development is a pivotal move towards submitting an Investigational New Drug application to the FDA for Lucid-21-302 in MS, marking a beacon of hope for millions affected by this debilitating condition.
Quantum BioPharma, through its subsidiary Huge Biopharma Australia Pty Ltd., is at the forefront of innovative biotech solutions, focusing on challenging neurodegenerative and metabolic disorders. The company's portfolio includes Lucid-MS, a patented compound that has shown efficacy in reversing myelin degradation in preclinical models. Additionally, Quantum BioPharma's strategic investments and its stake in Unbuzzd Wellness Inc. underscore its commitment to advancing healthcare solutions. For more details on this groundbreaking development, visit the full press release.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma Advances Lucid-MS for MS Treatment in Phase 2 Trial
